Small cap News

Riot Platforms shares rose more than 12% in intra-day trade on Wednesday, reaching their highest level since March 2022.

Entravision Communications reported an upbeat quarterly earnings, with management focusing on major political ad spend revenue in 2026.

The AI-driven system, known internally as “Leonardo,” will mass-produce natural killer (NK) immune cells capable of attacking cancer cells.

AMC also said it had eliminated one-third of the over $6 billion in pandemic-era debt and lease obligations.

The defense technology company had $17 million in backlog at the end of the first quarter.

ImmunityBio’s global expansion push has also gained momentum after progress at its Dunkirk, New York manufacturing facility.

Backblaze reported earnings per share of $0.04 on revenue of $38.7 million, while Wall Street analysts expected the company to report nil earnings on revenue of $37.8 million.

Shares of Circle Internet Group led large-cap gains, while retail sentiment on Stocktwits around the company flipped to ‘extremely bullish’ from ‘bearish’ over the past day.

The deal includes $1.85 billion in assumed debt and $2.35 billion in stock consideration.

Twin Vee PowerCats announced last week that its board of directors had approved a 1-for-37 reverse stock split of the company’s issued and outstanding common stock.

Vinay Prasad had earlier called ImmunityBio founder Patrick Soon-Shiong a “snake oil salesman” in a 2024 episode of The VPZD Show.

Sellas was invited to the European Parliament to discuss the EU Biotech Act, drug approvals, and market access.

The film will stream on Netflix starting April 2, with a 49-day exclusive theatrical window.

Musk posted “$10T or bust” on X after a founder compared his current wealth to John D. Rockefeller’s during the Industrial Revolution.

CEO Andrew Dudum replied “Message me” to an investor post calling the tech of a heart test firm of having “unreal value” and urging a buyer.

Its late-stage trial targets 120 patients globally, with results aimed at pushing for a potential NDA filing in 2029.

Bitcoin’s price rose to an intraday high of nearly $80,000 as oil prices eased after reports of a potential Iran-U.S. peace deal.

According to company data, 95% of users saw testosterone increases, with 80% reaching optimal levels within 60 days.

Sellas reported 2.64 million stock options and 2.26 million RSUs outstanding as of April 15, representing an equity overhang of about 2.6% of the total float.

Beyond Meat surged in April, gaining over 58%, as retail traders and short covering drove a meme-style rally.

The company’s primary cannabis asset remains its Gabriola Island cultivation site in British Columbia, where it operates under a hemp license.

The FCC replaced a 1990s spectrum framework that had limited transmission power for newer satellite constellations.

The license allows Gemini to clear regulated derivatives, including prediction market contracts, within its own platform.

USO’s ETF structure amplifies its sensitivity to geopolitical shocks, with 86% of its holdings in near-dated WTI futures.

Amazon CEO Andy Jassy said consumers, enterprises and governments increasingly expect uninterrupted connectivity beyond traditional networks.

TSLA stock is on track to snap a three-month losing streak, rising just over 1% so far in April.

The model directly challenges Tesla’s Model Y in China’s mid-premium EV segment as competition intensifies among local rivals.

The company has already begun hiring to restart the Dunkirk facility, identifying at least 19 roles across multiple functions.

On Tuesday, LCID stock slipped 1%, marking its fifth straight session of losses, while SNGX plunged 70% and SRAD fell 11%.

The drop came as Bitcoin slipped below $76,000, pressured by rising oil prices after the UAE announced it would be leaving OPEC in May.

GEMI’s stock is down 56% this year and remains more than 88% below its IPO debut high of $45.89 in September last year.

Commonwealth holds Sellas alongside major healthcare names like Eli Lilly, Pfizer, and UnitedHealth.

VKTX rose about 1.4% over the past month, beating Altimmune, Amgen, and Structure Therapeutics; however, Novo Nordisk led the pack with a 17.3% gain.

Meanwhile, Revolution Medicines has alleged potential patent infringement and trade-secret issues related to ERAS-0015.

In the earnings call, CEO Marcus Lemonis highlighted a turnaround plan that is starting to work.

Saudi Arabia’s Public Investment Fund (PIF) remains Lucid’s largest shareholder with a 50% stake in the EV firm.

Weaker demand, EV production efficiency, and financial health were on investors’ radar.

Amesite stated that it has entered into definitive agreements to purchase and sell 696,866 shares of its common stock at a price of $1.435 per share.

The company announced plans to prepay its loan and reaffirmed previously announced guidance.

The company announced it had bought 789 Bitcoin for around $61 million over the past week.

Peers including AAOI, LITE, and LWLG have already benefited from large optical-networking orders and multibillion-dollar infrastructure deals.

OGN stock is on track for a record monthly gain, rising 88% in April, including a 31% surge on Friday, its strongest session ever.

Sellas is seeking approval to add 20 million shares to its equity plan after nearly exhausting its current pool, with only 7,991 shares remaining.

The FDA stated that this will increase support for psychedelic-based medicines for the treatment of conditions like post-traumatic stress disorder, treatment-resistant depression, and major depressive disorder.

Lakewood-Amedex Biotherapeutics started trading on the Nasdaq on Thursday, closing the day with gains of over 8% and a market capitalization of $122 million.

The small-cap fintech is in focus following a potential AI pivot via partnership with Nano Labs.

An analyst said that the ruling could push the company to rely longer on lower-band spectrum for its rollout strategy.

Trump has also called on Congress to preserve access to full-spectrum CBD products and expand research.

Alliance Global raised its price target to $15 and reaffirmed its ‘Buy’ rating on the stock.

Consensus estimates compiled by Koyfin suggest ACB currently offers the strongest valuation upside.